Why choose our biosimilars?

Fresenius Kabi and biosimilars offer more

Fresenius Kabi has an enduring heritage of devotion towards providing high-quality and affordable products for the therapy and care of critically and chronically ill patients, with expertise in clinical nutrition, infusion therapies, IV drugs, infusion and transfusion medical devices and quality services. We continue to uphold our tradition of putting patients first with our new biosimilars offering. In addition to this commitment, our long-standing heritage in high-quality pharmaceutical development ensures the technical knowledge to develop biosimilars that are highly similar to the reference product in terms of structure, clinical efficacy and safety profile. 

Fresenius Kabi is committed to providing valued biologic treatments through the development of new immunology and oncology pipeline therapies in our expanding biosimilars portfolio.

Our mission includes working closely with healthcare professionals, payers and patients to develop value-added services based on genuine insights to improve patient care.

In fact, we strive to help patients go beyond the disease by seamlessly connecting biologic products with an innovative patient support program to leverage the value of comprehensive treatment packages that provide enhanced patient care.

For example, our patient support program, KabiCare, provides support to patients and improves patient/physician communication.

Fresenius Kabi is also an active member of Medicine for Europe, the European association for generic, biosimilars and value-added medicines. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes.

What types of biosimilars do we have in development? Learn here

IV, intravenous